[Effect of korvatone on hemodynamics in the acute stage of myocardial infarct]. 1981

Iu Belov, and T Daskalov, and K Chichovski, and G Kusitasev, and S Popnikolov

The pressure in pulmonary and brachial arteries, cardiac output and the period of isovolumetric contraction of left ventricle were measured prior to and by 15, 30 and 60 min post 4 mg corvaton sublingual administration in 20 patients with acute cardiac infarction by the third day after the disease onset (12--with normal diastolic pressure in pulmonary artery--under 1.87 kPa (14 mm Hg)--group I and 8--with elevated pressure--group II). The mean pressure in brachial artery was established to decrease more pronouncedly in group I (from 12.24 +/- 1.79 kPa (91.8 +/- 13.4 mm Hg to 10.45 +/- 1.61 kPa/78.4 +/- 12.1 mm Hg)--p less than 0.002) than in group II (from 11.96 +/- 1.49 kPa (89.11.2 mm Hg) to 11.22 +/- 1.32 kPa (84.2 +/- 9.9 mm Hg)--p less than 0.10). Heart rate was slightly accelerated in group I (from 83.6 +/- 6.21. min1 to 89.8 +/- 20.8.min-1--p less than 0.05) and in group II--an initial tendency to slow down (from 80.7 +/- 20.0.min-1 to 76.7 +/- 20.7.min61 beats, every 15 min, p less than 0.025). The pressure in pulmonary artery was slightly decreased in group I (average pressure--from 1.93 +/- 0.28 kPa (14.5 +/- 2.1 mm Hg) to 1.64 +/- 0.37 kPa (12.3 +/- 2.8 mm Hg, p less than 0.01), the decrease in group II was more manifested [average--from 3.96 +/- 0.61 kPa (29.7 +/- 4.6 mm Hg) to 3.29 +/- 0.77 kPa (24.7 +/- 5.8 mm Hg)--p less than 0.002 and diastolic--from 2.80 +/- 0.53 kPa (21.0 +/- 4.0 mm Hg) to 2.45 +/- 0.69 kPa (18.4 +/- 5.2 mm Hg)--p less than 0.01]. Those changes were accompanied by manifested reduction of cardiac index (from 3.02 +/- 1.06 to 2.47 +/- 0.61 1/min/m2, p less than 0.025), stroke index (from 36.2 +/- 10.4 to 29.1 +/- 6.9 cm3/m2, p less than 0.01) and stroke working index (from 42.1 +/- 14.7 to 29.2 +/- 9.0 g.m/m2, p less than 0.001) in group I, whereas in group II those indices under went no substantial changes (cardiac index--from 1.96 +/- 0.62 to 1.89 +/- 0.53 l/min/m3, stroke index--from 27.6 +/- 9.7 to 27.6 +/- 9.8 cm3/m2 and stroke working index--from 25.3 +/- 10.8 to 24.1 +/- 9.6 g.m/m2, p less than 00,1). The systemic vascular resitence and delta P/delta T of the left ventricle did not change in both groups (p less than 0,01). The changes in the hemodynamics developed gradually and were best manifested by the 60 min, but 50 per cent of the maximum effect was realized as early as the 15th min. Corvaton, was concluded, by the authors, to be useful in the treatment of the originated stasis cardiac insufficiency in those patients.

UI MeSH Term Description Entries
D008981 Molsidomine A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS. Morsydomine,Corpea,Corvaton,Duracoron,Fali-Cor,Korvatone,MTW-Molsidomin,Molsi 1A Pharma,Molsi-AZU,Molsi-Puren,Molsibeta,Molsicor,Molsidain,Molsidomin,Molsidomin Heumann,Molsidomin Stada,Molsidomin Von Ct,Molsidomin-Ratiopharm,Molsihexal,Molsiket,SIN-10,Sydnopharm,Fali Cor,Heumann, Molsidomin,MTW Molsidomin,Molsi AZU,Molsi Puren,Molsidomin Ratiopharm,SIN 10,SIN10,Von Ct, Molsidomin
D009025 Morpholines Tetrahydro-1,4-Oxazines,Tetrahydro 1,4 Oxazines
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010069 Oxadiazoles Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms. Oxadiazole
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006334 Heart Function Tests Examinations used to diagnose and treat heart conditions. Cardiac Function Tests,Cardiac Function Test,Function Test, Cardiac,Function Test, Heart,Function Tests, Cardiac,Function Tests, Heart,Heart Function Test,Test, Cardiac Function,Test, Heart Function,Tests, Cardiac Function,Tests, Heart Function
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D013558 Sydnones OXADIAZOLES bearing an oxygen at the 5-position. They are mesoionic, with delocalized positive and negative charges.

Related Publications

Iu Belov, and T Daskalov, and K Chichovski, and G Kusitasev, and S Popnikolov
May 1970, Klinische Wochenschrift,
Iu Belov, and T Daskalov, and K Chichovski, and G Kusitasev, and S Popnikolov
November 1976, Vrachebnoe delo,
Iu Belov, and T Daskalov, and K Chichovski, and G Kusitasev, and S Popnikolov
January 1974, Revista espanola de cardiologia,
Iu Belov, and T Daskalov, and K Chichovski, and G Kusitasev, and S Popnikolov
January 1980, Schweizerische medizinische Wochenschrift,
Iu Belov, and T Daskalov, and K Chichovski, and G Kusitasev, and S Popnikolov
January 1982, Vrachebnoe delo,
Iu Belov, and T Daskalov, and K Chichovski, and G Kusitasev, and S Popnikolov
July 1973, Vrachebnoe delo,
Iu Belov, and T Daskalov, and K Chichovski, and G Kusitasev, and S Popnikolov
January 1974, Verhandlungen der Deutschen Gesellschaft fur Kreislaufforschung,
Iu Belov, and T Daskalov, and K Chichovski, and G Kusitasev, and S Popnikolov
June 1987, Vrachebnoe delo,
Iu Belov, and T Daskalov, and K Chichovski, and G Kusitasev, and S Popnikolov
January 1979, Revista espanola de cardiologia,
Iu Belov, and T Daskalov, and K Chichovski, and G Kusitasev, and S Popnikolov
July 1974, Archives des maladies du coeur et des vaisseaux,
Copied contents to your clipboard!